Companies / BOC Sciences / Brodalumab
BOC Sciences

Brodalumab | BOC Sciences

Brodalumab is a human monoclonal antibody that binds to the interleukin-17 receptor and inhibits the binding of IL-17 to its receptor. Brodalumab has been approved for the treatment of moderate to severe plaque psoriasis.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.